2020 GAIRDNER ONTARIO INTERNATIONAL SYMPOSIUM

BREAKING THROUGH:
DELIVERING ON THE PROMISE OF GENE THERAPY

An international symposium on gene therapy research and practice
Registration is now open!

Breaking Through brings together Canadian and international leaders to explore the past, present, and future of somatic gene therapy research and practice. This two-day virtual event will examine the successes, challenges and opportunities from the bench to the bedside. It will also feature the CCA Expert Panel on the Approval and Use of Somatic Gene Therapies in Canada, who will discuss the findings and implications of their report, due to be released in November.

Join us for this live and interactive two-day event, available in both official languages.

#GairdnerSymposium

Speakers

Katherine A. High
Duncan J. Stewart
R. Alta Charo
Jay Ingram
Bartha Maria Knoppers
Ubaka Ogbogu
Christopher McCabe
Danica B. Stanimirovic
Durhane Wong-Rieger
Eric M. Meslin
Harold Atkins
Janet Rossant
Michel Sadelain
Murray Krahn
Michel Goldman
Michael Hayden
Ronald Cohn
Vardit Ravitsky
William Charnetski
Rob Annan

Agenda

Download Agenda
December 2, 2020
  • 11:00 am - 11:15 am
    WELCOME AND OPENING REMARKS
    Janet Rossant, PhD, C.C., FRSC
    President,
    Gairdner Foundation
    (Toronto, ON)
    Duncan J. Stewart, MD, FRCPC, FCAHS
    Executive Vice-President, Research,
    The Ottawa Hospital;
    Professor, University of Ottawa
    (Ottawa, ON)
  • 11:15 am - 11:55 am
    LIVING DRUGS: CAR T CELLS, FIRST FDA-APPROVED GENETICALLY ENGINEERED CELL THERAPY
    Michel Sadelain, MD, PhD
    Director, Center for Cell Engineering
    Stephen and Barbara Friedman Chair
    Member, Immunology Program
    Member, Departments of Medicine and Pediatrics
    Memorial Sloan-Kettering Cancer Center
    (New York, NY)
  • 12:00 pm - 12:40 pm
    Turning Genes into Medicines: Highlights and Hurdles in Development of Gene Therapies for Genetic Disease
    Katherine A. High, MD
    Professor Emerita, Perelman School of Medicine, University of Pennsylvania,
    Co-founder and former President and Head of R&D, Spark Therapeutics,
    Visiting Professor, Rockefeller University
    (Philadelphia, USA)
  • 12:45 pm - 1:25 pm
    Equity and Sustainability in Canadian Access to Gene Therapy Innovations
    Christopher McCabe, PhD
    CEO and Executive Director,
    Institute of Health Economics
    (Edmonton, AB)
  • 1:30 pm - 2:10 pm
    Gene therapies and the Common Good: a path to reasonable pricing?
    Michel Goldman, MD, PhD
    Emeritus professor and Founder of the Institute for Interdisciplinary Innovation in healthcare,
    Université libre de Bruxelles
    (Brussels, BE)
  • 2:10 pm - 2:15 pm
    CLOSING REMARKS
    Duncan J. Stewart, MD, FRCPC, FCAHS
    Executive Vice-President, Research,
    The Ottawa Hospital;
    Professor, University of Ottawa
    (Ottawa, ON)
December 3, 2020
  • 11:00 am - 11:10 am
    OPENING REMARKS
    Eric M. Meslin, PhD, FCAHS
    President and CEO,
    Council of Canadian Academies (CCA)
    (Ottawa, ON)
  • 11:10 am - 11:25 am
    Leave No One Behind: Multiple Pathways for Access to Transformative Therapies
    Durhane Wong-Rieger, PhD
    President and CEO,
    Canadian Organization for Rare Disorders (CORD)
    (Toronto, ON)
  • 11:30 am - 11:50 am
    Main Findings from the CCA's Expert Panel on the Approval and Use of Gene Therapies in Canada
    Janet Rossant, PhD, C.C., FRSC
    President,
    Gairdner Foundation
    (Toronto, ON)
  • 11:50 am - 12:15 pm
    DISCUSSION WITH THE CCA'S EXPERT PANEL ON THE approval and use of somatic gene therapies in canada
    Eric M. Meslin, PhD, FCAHS
    President and CEO,
    Council of Canadian Academies (CCA)
    (Ottawa, ON)
    Janet Rossant, PhD, C.C., FRSC
    President,
    Gairdner Foundation
    (Toronto, ON)
    Harold Atkins, MD, FRCPC
    Physician, The Ottawa Hospital;
    Scientist, Ottawa Hospital Research Institute
    (Ottawa, ON)
    William Charnetski, LLB
    Executive Vice President, Health System Solutions and Government Affairs, PointClickCare;
    Former Chief Health Innovation Strategist, Government of Ontario
    (Toronto, ON)
    Ubaka Ogbogu, LLB, SJD
    Associate Professor, Faculties of Law and Pharmacy and Pharmaceutical Sciences,
    University of Alberta
    (Edmonton, AB)
  • 12:25 pm - 1:20 pm
    GENE THERAPY: THE CANADIAN CONTEXT
    Danica B. Stanimirovic, MD, PhD
    Director Research, Translational Bioscience,
    National Research Council of Canada
    (Ottawa, ON)
    Title TBC
    Ronald Cohn, MD, FACMG, FCAHS
    President and CEO,
    The Hospital for Sick Children (SickKids)
    (Toronto, ON)
    GLYBERA REINVENTED: A WINDING STORY OF COMMITMENT, CREATIVITY, AND INNOVATION
    Michael Hayden, MB, ChB, PhD, FRCP(C), FRSC, C.M., O.B.C
    University Killam Professor, Senior Scientist, Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics,
    University of British Columbia
    (Vancouver, BC)
    Bartha Maria Knoppers, PhD, O.C., O.Q., FRSC, FCAHS
    Full Professor and Director, Centre of Genomics and Policy, Faculty of Medicine, Human Genetics,
    McGill University
    (Montréal, QC)
    Title TBC
    Murray Krahn, MD, MSc
    Professor and Tier 1 Canada Research Chair, University of Toronto,
    Director, THETA (Toronto Health Economics and Technology Assessment Collaborative)
    (Toronto, ON)
  • 1:30 pm - 2:25 pm
    COMING SOON: THE FUTURE OF GENE EDITING AND GENE THERAPIES
    Sponsored by: Genome Canada
    Rob Annan, PhD
    President and CEO,
    Genome Canada
    (Ottawa, ON)
    R. Alta Charo, J.D.
    Warren P. Knowles Professor of Law & Bioethics,
    University of Wisconsin Law School
    (Madison, USA)
    Jay Ingram, C.M.
    Science broadcaster and writer, Former Co-Host, Discovery Channel’s “Daily Planet”
    (Calgary, AB)
    Vardit Ravitsky, PhD, FCAHS
    Full Professor, Bioethics Program, Department of Social and Preventative Medicine, School of Public Health,
    Université de Montréal;
    President, International Association of Bioethics
    (Montréal, QC)
    Janet Rossant, PhD, C.C., FRSC
    President,
    Gairdner Foundation
    (Toronto, ON)
  • 2:25 pm - 2:30 pm
    CLOSING REMARKS
    Eric M. Meslin, PhD, FCAHS
    President and CEO,
    Council of Canadian Academies (CCA)
    (Ottawa, ON)

Sponsors and Partners

This event was made possible thanks to the generous support of the following partners and sponsors:

Partners

Sponsors

Gold

Silver

Bronze

FAQ

Is this symposium free?

Yes, the symposium is free, but registration is required.

Simply click on the “Register Now” button at the top of the page.

Your registration includes both days. Once you register you will receive a URL link to the event viewer. Sessions are live and you are welcome to join sessions as your availability permits.

Wherever you are! This is an all-virtual online symposium that will take place live on December 2-3, 2020 (see agenda for details). You can access the livestream using any browser or device (other than Internet Explorer).

Yes, if you register on the French page the link you receive will be for the French video feed. While the speakers will be presenting in English, there will be simultaneous translation to French.

Yes, all the presentations will be recorded and made available on CCA’s YouTube channel shortly after the event.

Every year, the Gairdner Foundation invites universities, organizations, and research institutes across Ontario to submit proposals to host a partnered international symposium on topics exploring the frontiers of biomedicine. The Council of Canadian Academies (CCA) and the Ottawa Hospital Research Institute are honoured to have been selected to host the 2020 Gairdner Ontario International Symposium on gene therapy.

Notice regarding COVID-19
Learn more